DK1751184T3 - FGF-21 fusionsproteiner - Google Patents

FGF-21 fusionsproteiner

Info

Publication number
DK1751184T3
DK1751184T3 DK05742237T DK05742237T DK1751184T3 DK 1751184 T3 DK1751184 T3 DK 1751184T3 DK 05742237 T DK05742237 T DK 05742237T DK 05742237 T DK05742237 T DK 05742237T DK 1751184 T3 DK1751184 T3 DK 1751184T3
Authority
DK
Denmark
Prior art keywords
fgf
fusion proteins
specific
obesity
diabetes
Prior art date
Application number
DK05742237T
Other languages
Danish (da)
English (en)
Inventor
Wolfgang Glaesner
Rohn Lee Junior Millican
Yu Tian
Sheng-Hung Rainbow Tschang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1751184T3 publication Critical patent/DK1751184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05742237T 2004-05-13 2005-05-02 FGF-21 fusionsproteiner DK1751184T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57090804P 2004-05-13 2004-05-13
PCT/US2005/015111 WO2005113606A2 (fr) 2004-05-13 2005-05-02 Proteines de fusion fgf-21

Publications (1)

Publication Number Publication Date
DK1751184T3 true DK1751184T3 (da) 2009-11-23

Family

ID=92541399

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05742237T DK1751184T3 (da) 2004-05-13 2005-05-02 FGF-21 fusionsproteiner

Country Status (12)

Country Link
US (1) US7576190B2 (fr)
EP (2) EP1751184B1 (fr)
JP (1) JP2008506635A (fr)
AT (1) ATE444306T1 (fr)
CA (1) CA2565300A1 (fr)
DE (1) DE602005016917D1 (fr)
DK (1) DK1751184T3 (fr)
ES (1) ES2332100T3 (fr)
PL (1) PL1751184T3 (fr)
PT (1) PT1751184E (fr)
SI (1) SI1751184T1 (fr)
WO (1) WO2005113606A2 (fr)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
EA011390B1 (ru) 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2693504A1 (fr) 2007-08-03 2009-02-12 Eli Lilly And Company Traitement de l'obesite
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP2296690B1 (fr) 2008-06-04 2016-11-30 Amgen, Inc Mutants fgf21 et leurs utilisations
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
BRPI1007313A2 (pt) 2009-01-23 2016-02-10 Novo Nordisk As derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
EP2427207B1 (fr) 2009-05-05 2017-08-16 Amgen, Inc Mutants de fgf21 et leurs utilisations
HRP20240135T1 (hr) * 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
WO2011154349A2 (fr) 2010-06-08 2011-12-15 Novo Nordisk A/S Analogues et dérivés du fgf21
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
EP2679234A3 (fr) 2009-12-02 2014-04-23 Amgen Inc. Protéines de liaison qui se lient au FGFR1C humain, au beta-klotho humain et aux deux ensemble
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2460527A1 (fr) 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
CA2796459C (fr) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Procedes de traitement de troubles metaboliques utilisant le fgf-1
EP2595647A1 (fr) * 2010-07-20 2013-05-29 Novo Nordisk A/S Composés fgf21 n-terminaux modifiés
JP2014500248A (ja) * 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
WO2013006486A2 (fr) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, utilisations et procédés pour le traitement de troubles et de maladies métaboliques
EP2548570A1 (fr) 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
JP6165168B2 (ja) 2011-12-22 2017-07-19 ファイザー・インク 抗糖尿病化合物
JP6400480B2 (ja) 2012-02-15 2018-10-03 ノヴォ ノルディスク アー／エス ペプチドグリカン認識タンパク質１に結合する抗体
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
SMT201700488T1 (it) 2012-02-15 2017-11-15 Novo Nordisk As Anticorpi che legano e bloccano il recettore d'innesco espresso sulle cellule mieloidi-1 (trem-1)
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
CA2871656A1 (fr) 2012-06-11 2013-12-19 Eli Lilly And Company Variants du facteur de croissance des fibroblastes 21
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
DK3421486T5 (da) * 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
EP3057605A1 (fr) 2013-10-18 2016-08-24 Novartis AG Méthodes de traitement du diabete et de troubles associés
AU2014340241B2 (en) 2013-10-21 2018-11-01 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
WO2015065897A1 (fr) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Modèles de cancer et procédés associés
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
EP3160496B1 (fr) * 2014-06-24 2021-03-03 Novo Nordisk As Protéines de fusion mic-1 et utilisations associées
EP3172232B1 (fr) 2014-07-17 2023-12-27 Novo Nordisk A/S Mutagenèse dirigée sur site d'anticorps trem-1 pour réduire la viscosité.
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
AR103246A1 (es) 2014-12-23 2017-04-26 Novo Nordiks As Derivados de fgf21 y sus usos
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2016207717A1 (fr) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anticorps et fragments anti-vista
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
WO2017075260A1 (fr) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
CN109414471A (zh) 2016-05-24 2019-03-01 诺和诺德股份有限公司 Mic-1化合物及其用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
EP3503882A4 (fr) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
EP4470551A3 (fr) * 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
MX2020002206A (es) 2017-09-08 2020-07-20 Bristol Myers Squibb Co Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
US20200376080A1 (en) 2017-12-22 2020-12-03 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
CN111727055B (zh) * 2018-02-06 2024-06-25 温哥华生物技术有限公司 GHR-106单克隆抗体作为GnRH拮抗剂的用途
AU2019218147B2 (en) 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
EP3774902A1 (fr) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anticorps anti-trem-1 et utilisations associées
CA3104686A1 (fr) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Formulations de fgf21
CN111195349B (zh) * 2018-11-16 2023-02-24 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干粉制剂
CN111662373B (zh) 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
IL294534A (en) 2020-01-08 2022-09-01 Bristol Myers Squibb Co Fgf-21 conjugate formulations
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
EP4230216A4 (fr) * 2020-07-24 2025-02-19 Jiangsu Gensciences Inc. Protéine de fusion insuline-fc et son application
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
CA3224743A1 (fr) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptides de fusion pour troubles metaboliques
WO2024132147A1 (fr) 2022-12-22 2024-06-27 Lifearc Agonistes du récepteur de la galanine-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US606830A (en) 1898-07-05 Insulator
US528582A (en) 1894-11-06 Can-opener
US606805A (en) 1898-07-05 Can-opener
US635882A (en) 1898-11-02 1899-10-31 Henry Torrance Jr Refrigerating system.
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
WO2001036640A2 (fr) 1999-11-18 2001-05-25 Chiron Corporation Gene humain fgf-21 et produits d'expression genique
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US20070253966A1 (en) * 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins

Also Published As

Publication number Publication date
PL1751184T3 (pl) 2010-02-26
EP1751184A2 (fr) 2007-02-14
EP1751184B1 (fr) 2009-09-30
DE602005016917D1 (de) 2009-11-12
CA2565300A1 (fr) 2005-12-01
US7576190B2 (en) 2009-08-18
EP2194064A1 (fr) 2010-06-09
ES2332100T3 (es) 2010-01-26
WO2005113606A2 (fr) 2005-12-01
SI1751184T1 (sl) 2010-01-29
US20070237768A1 (en) 2007-10-11
PT1751184E (pt) 2009-11-10
JP2008506635A (ja) 2008-03-06
ATE444306T1 (de) 2009-10-15
WO2005113606A3 (fr) 2006-05-04

Similar Documents

Publication Publication Date Title
DK1751184T3 (da) FGF-21 fusionsproteiner
WO2005091944A3 (fr) Composes fgf-21 lies au glycol
ATE517120T1 (de) Igf-1 fusion polypeptide und deren therapeutische verwendung
ATE406384T1 (de) Glp-1 fusion proteine
EP1845105A4 (fr) Exendines modifiees et utilisations correspondantes
ATE396738T1 (de) Verwendung von glp-2-peptiden
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
DE602006017202D1 (de) Pegylierte glp-1-verbindungen
BR0210383A (pt) compostos para o tratamento de distúrbios metabólicos
EP1507556A4 (fr) Conjugues de type vecteur-derive de calicheamicine
ATE467642T1 (de) Derivatisierung des granulozytenkoloniestimulierenden faktors
ITRM20010464A1 (it) Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
ES2185595T3 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
ATE307845T1 (de) N-alkylaziridinoprepolymere als dentalmasse
BRPI0414008B8 (pt) compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula
DE60126994D1 (de) Stabilisierung von radiopharmazeutischen zusammensetzungen mit einem hydrophilen thioether oder einem hydrophilen 6-hydroxy-chroman
ATE384423T1 (de) Heuwerbungsmaschine
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
ATE372990T1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren
DE60213827D1 (de) Antikörper gegen Caspase-8, ihre Herstellung und Verwendung
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
ITBO20050140A1 (it) Tessuto con principi attivi e metodo collegato di ricarica dei principi attivi
ATE502047T1 (de) T-helper antigenic determinant (thd) peptide
FR2845898B1 (fr) Composition cosmetique associant au moins deux matieres colorantes dont au moins une matiere colorante photochrome.